Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Tiziana Life Sciences Ltd
(NQ:
TLSA
)
1.210
+0.030 (+2.54%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Tiziana Life Sciences Ltd
< Previous
1
2
3
4
5
6
7
8
Next >
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
March 05, 2024
Via
Benzinga
Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease
March 05, 2024
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
7 Over-Hyped Stocks to Sell Before They Plunge
January 25, 2024
It wasn't too long ago that these stocks were considered hot commodities. But now they're just overhyped stocks to sell.
Via
InvestorPlace
Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients
January 08, 2024
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024
January 05, 2024
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation
January 05, 2024
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis
December 19, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tesla Shares Hardly Damaged Despite Recall: Full Self-Driving Is Elon Musk's 'Holy Grail,' Analyst Says
December 13, 2023
Tesla shares fell only slightly. And auto recalls are nothing new. Recall how, in 1981, Ford issued a recall on 21 million vehicles.
Via
Benzinga
Topics
Product Recall
Exposures
Legal
Product Safety
Don't Get Caught In Equity Rally Hype: Lessons From 2023 To Remember In 2024
December 12, 2023
After a volatile 2023, equity markets appear to be rallying into 2024. Can they keep it up?
Via
Benzinga
Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar
December 04, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Expects To Start Enrolling Patients in Its Phase 2 Clinical Trial To Treat Secondary Progressive Multiple Sclerosis (SPMS) Using its Novel Intranasal Monoclonal Antibody Foralumab
December 01, 2023
--News Direct--
Via
News Direct
Tiziana Expects To Start Enrolling Patients In Its Phase 2 Clinical Trial To Treat Secondary Progressive Multiple Sclerosis (SPMS) Using Its Novel Intranasal Monoclonal Antibody Foralumab
November 30, 2023
This month, Tiziana Life Sciences (NASDAQ: TLSA) expects to start enrolling patients for a phase 2a trial of Foralumab, an immunomodulation therapy for Secondary Progressive Multiple Sclerosis (SPMS)...
Via
Benzinga
Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis
November 30, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
SPDR ETF Report For Tuesday, November 21
November 22, 2023
Via
Talk Markets
Topics
ETFs
Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023
November 01, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
October 19, 2023
We're starting off Thursday with a breakdown of the biggest pre-market stock movers traders need to know about this morning!
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
October 18, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
October 18, 2023
Pre-market stock movers are a hot topic worth checking out on Wednesday and we have all the latest news happening this morning!
Via
InvestorPlace
Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment
October 18, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 17, 2023
Via
Benzinga
Tiziana Life Sciences reveals "exciting" clinical data from latest MS trial
October 17, 2023
--News Direct--
Via
News Direct
Tiziana Life Sciences reveals "exciting" clinical data from latest MS trial
October 17, 2023
Tiziana Life Sciences Ltd (NASDAQ:TLSA) chief medical officer and chief operating officer Matthew Davis speaks to Thomas Warner from Proactive after the clinical-stage biopharmaceutical company...
Via
TheNewswire.com
Tiziana Life Sciences reports six-month PET scan results for MS patients
October 16, 2023
--News Direct--
Via
News Direct
Tiziana Life Sciences reports six-month PET scan results for MS patients
October 16, 2023
Tiziana Life Sciences Ltd (NASDAQ:TLSA) chief medical officer and chief operating officer Matthew Davis speaks to Thomas Warner from Proactive after the clinical-stage biopharmaceutical company...
Via
TheNewswire.com
Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab
October 16, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana to Announce Six-Month Human Safety and Biomarker Data at the ECTRIMS Annual Congress, Following-Up from Positive Outcomes Data Presented in June
October 13, 2023
--News Direct--
Via
News Direct
Exposures
Product Safety
Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS)
October 13, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana To Announce Six-Month Human Safety And Biomarker Data At The ECTRIMS Annual Congress, Following-Up From Positive Outcomes Data Presented In June
October 12, 2023
Tiziana (NASDAQ: TLSA) is following up with anticipated human data and announced the acceptance of a late-breaking poster at the 39th Congress of the Europea
Via
Benzinga
Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress
October 11, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Advances Phase 2 Site Selection for Its Lead Clinical Program in Non-Active Secondary Progressive Multiple Sclerosis (SPMS) and The Company Prepares for Six-Month Clinical Data Update
October 05, 2023
--News Direct--
Via
News Direct
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.